MCID: CNN002
MIFTS: 40

Cannabis Abuse

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

MalaCards integrated aliases for Cannabis Abuse:

Name: Cannabis Abuse 12 55 15 72
Marijuana Abuse 12 55 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9505
ICD9CM 35 305.2
MeSH 44 D002189
SNOMED-CT 68 37344009
ICD10 33 F12.1
UMLS 72 C0006868 C0024809

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to substance abuse and cannabis dependence. An important gene associated with Cannabis Abuse is CNR2 (Cannabinoid Receptor 2), and among its related pathways/superpathways are Ras signaling pathway and Neuroscience. The drugs Topiramate and Buspirone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and lung.

Related Diseases for Cannabis Abuse

Diseases related to Cannabis Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 substance abuse 30.6 COMT BDNF
2 cannabis dependence 30.5 COMT CNR1
3 substance dependence 30.0 CNR1 BDNF
4 personality disorder 29.9 COMT BDNF
5 polysubstance abuse 29.6 COMT CNR1
6 anxiety 29.5 COMT CNR1 BDNF
7 drug dependence 29.5 CNR1 CHRNB3 BDNF
8 alcohol dependence 29.3 COMT CNR1 BDNF
9 neuropathy, hereditary sensory and autonomic, type v 10.3 NGF BDNF
10 adult astrocytic tumour 10.3 NGF BDNF
11 paine syndrome 10.3 NGF BDNF
12 ocular dominance 10.2 NGF BDNF
13 schizophrenia 10.2
14 psychotic disorder 10.2
15 tendinosis 10.2 CNR1 BDNF
16 alcohol use disorder 10.2
17 interstitial cystitis 10.2 NGF BDNF
18 amnestic disorder 10.2 CNR1 BDNF
19 autonomic nervous system neoplasm 10.1 NGF BDNF
20 severe combined immunodeficiency 10.1
21 peripheral nervous system neoplasm 10.1 NGF BDNF
22 toxic encephalopathy 10.1 NGF BDNF
23 antisocial personality disorder 10.0
24 visual epilepsy 10.0
25 seizure disorder 10.0
26 attention deficit-hyperactivity disorder 10.0
27 cyclic vomiting syndrome 10.0
28 stroke, ischemic 10.0
29 major affective disorder 8 10.0
30 major affective disorder 9 10.0
31 alexithymia 10.0
32 conduct disorder 10.0
33 bipolar disorder 10.0
34 cerebrovascular disease 10.0
35 diabetic neuropathy 10.0 NGF CNR1
36 traumatic brain injury 9.9 COMT BDNF
37 brain injury 9.9 COMT BDNF
38 membranous nephropathy 9.9
39 atrial fibrillation 9.9
40 focal segmental glomerulosclerosis 9.9
41 glomerulonephritis 9.9
42 mood disorder 9.9
43 acute myocardial infarction 9.9
44 paranoid schizophrenia 9.9 COMT BDNF
45 postpartum depression 9.9 COMT BDNF
46 chiari malformation type i 9.9
47 hand skill, relative 9.9
48 chiari malformation type ii 9.9
49 myocardial infarction 9.9
50 preterm premature rupture of the membranes 9.9

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
3
Clozapine Approved Phase 4 5786-21-0 2818
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Haloperidol Approved Phase 4 52-86-8 3559
9 Anticonvulsants Phase 4
10 Hypoglycemic Agents Phase 4
11 Antidepressive Agents Phase 4
12 Quetiapine Fumarate Phase 4 111974-72-2
13 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
14 Antidepressive Agents, Second-Generation Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Tranquilizing Agents Phase 4
17 Anti-Anxiety Agents Phase 4
18 Serotonin Agents Phase 4
19 Serotonin Antagonists Phase 4
20 Antipsychotic Agents Phase 4
21 Dopamine Agents Phase 4
22 Dopamine Antagonists Phase 4
23 Antiemetics Phase 4
24 Gastrointestinal Agents Phase 4
25 Dermatologic Agents Phase 4
26 Haloperidol decanoate Phase 4
27 Antipruritics Phase 4
28 Neurotransmitter Agents Phase 4
29 Adrenergic Agents Phase 4
30 Neurotransmitter Uptake Inhibitors Phase 4
31 Atomoxetine Hydrochloride Phase 4
32
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
33
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
34
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
35
Diphenhydramine Approved, Investigational Phase 2, Phase 3 58-73-1, 147-24-0 3100
36
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
37
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
38
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
39
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
40
Nicotine Approved Phase 3 54-11-5 942 89594
41
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
42
Vortioxetine Approved, Investigational Phase 2, Phase 3 508233-74-7 9966051
43
Amphetamine Approved, Illicit, Investigational Phase 2, Phase 3 300-62-9 5826 3007
44
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
45
Dronabinol Approved, Illicit Phase 2, Phase 3 1972-08-3 16078
46
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
47
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
48 Excitatory Amino Acid Antagonists Phase 2, Phase 3
49 Excitatory Amino Acids Phase 2, Phase 3
50 Antimanic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Unknown status NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
2 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
3 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
4 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
5 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
6 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
7 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
8 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
9 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Recruiting NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
10 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
11 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
12 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
13 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
14 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
15 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
16 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
17 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
18 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
19 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
20 Facilitating the Behavioral Treatment of Cannabis Use Disorder Completed NCT02946489 Phase 2, Phase 3 CI-581a
21 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
22 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
23 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
24 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
25 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
26 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
27 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
28 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Recruiting NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
29 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Recruiting NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
30 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Recruiting NCT03481959 Phase 3 Methylphenidate
31 Safety and Efficacy of PPP011-kit for Improving Health Related Quality of Life in Patients With Advanced Cancer and Uncontrolled Symptoms: A Randomized, Double-blind, Placebo-Controlled, Parallel Group Study Not yet recruiting NCT04001010 Phase 3 PPP011;Placebo
32 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
33 Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study- Terminated NCT01071135 Phase 3 Quetiapine XR
34 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
35 Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
36 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
37 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
38 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
39 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
40 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
41 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
42 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
43 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT00350285 Phase 2
44 Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment Completed NCT00142961 Phase 2 Atomoxetine
45 A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence Completed NCT00360191 Phase 2 Buspirone
46 A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
47 The Effect of Prescription Medications in Marijuana Users Completed NCT00893074 Phase 1, Phase 2 Dronabinol 30mg/day;Dronabinol 60mg/day;Dronabinol 120mg/day;Placebo
48 Gabapentin for Cannabis Withdrawal and Use Completed NCT00395044 Phase 2 Placebo;Gabapentin
49 Effects of Bupropion on Marijuana Withdrawal Symptoms Completed NCT00142870 Phase 2 Bupropion
50 Effects of Dronabinol (Oral THC) on Cannabis Use Completed NCT01394185 Phase 1, Phase 2 Dronabinol 120mg/day;Placebo;Dronabinol 240mg/day

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

41
Brain, Testes, Lung, Eye, Cortex, Spinal Cord, Breast

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 695)
# Title Authors PMID Year
1
Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. 9 38
16540246 2006
2
Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. 9 38
15500971 2004
3
Cannabis Abuse and Elevated Risk of Myocardial Infarction in the Young: A Population-Based Study. 38
31378243 2019
4
Demographic, Cannabis Use, and Depressive Correlates of Cannabis Use Consequences in Regular Cannabis Users. 38
31016818 2019
5
Sexual orientation and mental health over the life course in a birth cohort. 38
31190681 2019
6
Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. 38
30790675 2019
7
Neuregulin-1 is increased in schizophrenia patients with chronic cannabis abuse: Preliminary results. 38
30799217 2019
8
Cannabis abuse and dependence in kidney transplant candidates. 38
31003856 2019
9
Marijuana Induced Sick Sinus Syndrome: A Case Report. 38
31227686 2019
10
Threat Responsiveness as a Function of Cannabis and Alcohol Use Disorder Severity. 38
31170004 2019
11
Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. 38
31092662 2019
12
Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. 38
30448107 2019
13
Marijuana smoking and markers of testicular function among men from a fertility centre. 38
30726923 2019
14
Trace Detection of Tetrahydrocannabinol in Body Fluid via Surface-Enhanced Raman Scattering and Principal Component Analysis. 38
30907578 2019
15
Differential dysfunctions related to alcohol and cannabis use disorder symptoms in reward and error-processing neuro-circuitries in adolescents. 38
30710868 2019
16
The relationship between motivations for cannabis consumption and problematic use. 38
31018002 2019
17
Context matters: Characteristics of solitary versus social cannabis use. 38
30779237 2019
18
Disappearance of Tramadol and THC-COOH in Hair After Discontinuation of Abuse. Two Different Profiles. 38
30715334 2019
19
[Risk factors for the development of schizophrenia]. 38
30802921 2019
20
The epigenetic modulation of alcohol/ethanol and cannabis exposure/co-exposure during different stages. 38
30958117 2019
21
Posttraumatic Stress Disorder Is a Risk Factor for Multiple Addictions in Police Officers Hospitalized for Alcohol. 38
31117072 2019
22
Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse. 38
30572414 2019
23
Longitudinal Alterations in Prefrontal Resting Brain Connectivity in Non-Treatment-Seeking Young Adults With Cannabis Use Disorder. 38
31404267 2019
24
Case-control study analysis of DRD2 gene polymorphisms in drug addicted patients. 38
30659563 2018
25
Potential of an Interactive Drug Prevention Mobile Phone App (Once Upon a High): Questionnaire Study Among Students. 38
30514697 2018
26
The relationship of IQ and emotional processing with insula volume in schizophrenia. 38
29954697 2018
27
Marijuana-associated ST-elevation myocardial infarction: is this a benign drug. 38
30567245 2018
28
Childhood adversities are different in Schizophrenic Spectrum Disorders, Bipolar Disorder and Major Depressive Disorder. 38
30567512 2018
29
Medical cannabis use in older patients: Update on medical knowledge. 38
30415756 2018
30
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 38
30627731 2018
31
Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design. 38
29530110 2018
32
Cannabinoids for the treatment of cannabis abuse disorder. 38
30339139 2018
33
The interplay between externalizing disorders polygenic risk scores and contextual factors on the development of marijuana use disorders. 38
30195949 2018
34
Impact of comorbid cannabis use on outcome in first episode psychosis. 38
27592556 2018
35
Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013. 38
29095419 2018
36
The association between physical pain and cannabis use in daily life: An experience sampling method. 38
30165330 2018
37
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. 38
30239074 2018
38
Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. 38
29463913 2018
39
Prevalence of consumption of psychoactive substances amongst Moroccan taxi drivers. 38
30168502 2018
40
Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. 38
29146020 2018
41
Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review. 38
29117908 2018
42
The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. 38
29124816 2018
43
Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review. 38
28822116 2018
44
The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing. 38
29505682 2018
45
Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. 38
29066258 2018
46
Frequent Drug Use and Negative Employment Outcomes among the Criminally Active. 38
29172877 2018
47
Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study. 38
29614983 2018
48
Age at Onset and Social Cognitive Impairment in Clinically Stabilized Patients with Schizophrenia: An Ecological Cross-Sectional Study. 38
29997653 2018
49
Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: emerging disparities in vulnerable populations. 38
29265574 2018
50
Subcortical Local Functional Hyperconnectivity in Cannabis Dependence. 38
29486870 2018

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.26 NGF COMT CNR2 BDNF
2 axon GO:0030424 8.92 NGF COMT CNR1 BDNF

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.63 COMT CNR2 CNR1
2 neuron projection morphogenesis GO:0048812 9.57 NGF BDNF
3 modulation of chemical synaptic transmission GO:0050804 9.56 NGF BDNF
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.55 CNR2 CNR1
5 sensory perception of pain GO:0019233 9.54 CNR2 CNR1
6 response to nicotine GO:0035094 9.52 CNR1 CHRNB3
7 regulation of neuron differentiation GO:0045664 9.51 NGF BDNF
8 peripheral nervous system development GO:0007422 9.49 NGF BDNF
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.48 NGF BDNF
10 nerve development GO:0021675 9.43 NGF BDNF
11 memory GO:0007613 9.43 NGF CNR1 BDNF
12 nerve growth factor signaling pathway GO:0038180 9.4 NGF BDNF
13 negative regulation of nitric-oxide synthase activity GO:0051001 9.37 CNR2 CNR1
14 positive regulation of collateral sprouting GO:0048672 9.32 NGF BDNF
15 negative regulation of mast cell activation GO:0033004 9.16 CNR2 CNR1
16 negative regulation of action potential GO:0045759 8.96 CNR2 CNR1
17 cannabinoid signaling pathway GO:0038171 8.62 CNR2 CNR1

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cannabinoid receptor activity GO:0004949 8.62 CNR2 CNR1

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....